Havens Advisors’s Pacific Biosciences PACB Stock Holding History

Havens Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-56,000	Closed	-$553K	–	42
2020 Q3	$553K	Sell	56,000 -240,000	-81%	-$1.38M	0.51%	26
2020 Q2	$1.02M	Sell	296,000 -12,664	-4%	-$43.1K	1.52%	16
2020 Q1	$945K	Buy	308,664 +300,293	+3,587%	+$1.23M	0.92%	22
2019 Q4	$43K	Sell	8,371 -570,129	-99%	-$2.9M	0.04%	31
2019 Q3	$2.98M	Sell	578,500 -33,000	-5%	-$185K	2.72%	12
2019 Q2	$3.7M	Sell	611,500 -26,500	-4%	-$186K	2.6%	15
2019 Q1	$4.61M	Buy	638,000 +12,000	+2%	+$86.8K	4.47%	11
2018 Q4	$4.63M	Buy	+626,000	New	+$3.97M	4.3%	10

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Havens Advisors's PACB Position: Q4 2020 in Review

Havens Advisors sold out of Pacific Biosciences (PACB) in Q4 2020, closing a stake of 56,000 shares — an estimated $553K sold.

Havens Advisors first reported a position in PACB in Q4 2018 and held it in 8 quarters. The position peaked at $4.63M in Q4 2018. 210 funds tracked by Wall St. Rank hold PACB as of Q4 2020.

Havens Advisors reported no remaining Pacific Biosciences position as of Q4 2020 after selling out during the quarter.
Havens Advisors sold 56,000 Pacific Biosciences shares in Q4 2020, an estimated $553K.
Havens Advisors first reported a position in Pacific Biosciences in Q4 2018 and held it in 8 quarters.
Havens Advisors's Pacific Biosciences position peaked at $4.63M in Q4 2018.
210 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2020.

Based on Havens Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.